Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 5 USD 1.42% Market Closed
Market Cap: 406.9m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Codexis Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
Cash from Investing Activities
-$53m
CAGR 3-Years
-42%
CAGR 5-Years
-68%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Investing Activities
-$6.2B
CAGR 3-Years
-17%
CAGR 5-Years
-27%
CAGR 10-Years
6%
Danaher Corp
NYSE:DHR
Cash from Investing Activities
-$7.3B
CAGR 3-Years
17%
CAGR 5-Years
-42%
CAGR 10-Years
-22%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Investing Activities
-$103.9m
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
-1%
Agilent Technologies Inc
NYSE:A
Cash from Investing Activities
-$1.3B
CAGR 3-Years
-19%
CAGR 5-Years
5%
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Cash from Investing Activities
-$1.3B
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-24%
No Stocks Found

Codexis Inc
Glance View

Market Cap
406.9m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.99 USD
Overvaluation 40%
Intrinsic Value
Price

See Also

What is Codexis Inc's Cash from Investing Activities?
Cash from Investing Activities
-53m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's Cash from Investing Activities amounts to -53m USD.

What is Codexis Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-68%

Over the last year, the Cash from Investing Activities growth was -794%. The average annual Cash from Investing Activities growth rates for Codexis Inc have been -42% over the past three years , -68% over the past five years .

Back to Top